Abstract: Objective  To investigate the clinical efficacy and safety of tirofiban in stent thrombectomy for acute ischemic stroke. Methods  A total of  66 patients with acute ischemic stroke who received endovascular sent mechanical thrombectomy in the Gansu Provincial Hospital Department of Cerebrovascular Disease Center were includedfrom December 2015 to August 2017 .They were divided into thrombectomy plus tirofiban group(n=32) and stent thrombectomy alone (n=34) . Postoperative blood perfusion of the two groups was evaluated by Thrombolysis Incerebral Infarction（TICI）  blood flow fractionation. All patients underwent NIHSS score at 4 hours，24 hours and 14 days after operation. The Heidelberg Bleeding Classification was used to identify symptomatic intracrainal hemorrahage （SICH）  after operation. The modified Rankin scale was used to evaluated the patients fuctional outcome after 3 months. Results  The refusion TICI blood flow fractionation was increased after tirofiban treatment and the rate of TICI 3 stage blood flow of tirofiban group was significantly higher than that of the single embolectomy group(P＜0.05),  and the NIHSS score at 14 days after operation of tirofiban group was significantly improved(P＜0.05), The mRS score was significantly improved in the tirofiban group compared with that in the simple stent thrombectomy group after 90 days (P＜0.05),No significant difference was found in reinfarction rate and symptomatic bleeding after operatione in two groups（P＞0.05）.Conclusion  Tirofiban treatment during stent embolization in patients with AIS can improve vascular reperfusion and prognosis without increasing the risk of bleeding.

Key words: brain infarction, tirofiban, stent thrombectomy; , safety